Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26077180 | 0.95 | ALDH1A1 (0.40) | ALDH1A1CHRNA7PKMKDM4EMAPT | |
| SCHEMBL441543 | 0.95 | PRKCG (0.37) | ALDH1A1CHRNA7PKMKDM4EMAPT | |
| SCHEMBL10237822 | 0.87 | ALDH1A1 (0.38) | ALDH1A1CHRNA7PKMKDM4EMAPT | |
| SCHEMBL23710822 | 0.85 | ALDH1A1 (0.36) | ALDH1A1CHRNA7PKMMAPTSMN1; SMN2 | |
| SCHEMBL12045016 | 0.84 | — | — | |
| SCHEMBL8648295 | 0.82 | — | — | |
| SCHEMBL57306 | 0.82 | — | — | |
| SCHEMBL21954031 | 0.82 | HRH3 (0.38) | ALDH1A1CHRNA7PKMKDM4EMAPT | |
| SCHEMBL14261286 | 0.80 | SMN1; SMN2 (0.40) | ALDH1A1CHRNA7PKMKDM4EMAPT | |
| SCHEMBL18085476 | 0.80 | SMN1; SMN2 (0.40) | ALDH1A1CHRNA7PKMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| EP-3010883-B1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M INNOVATIVE PROPERTIES CO (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-9884831-B2 | Azocane and azonane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170183299-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-06-29 | — | — | US | disclosed |
| US-9670149-B2 | Process for preparing guanidino-functional monomers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160272599-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-09-22 | — | — | US | disclosed |
| EP-3010883-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M Innovative Properties Company (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160096802-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2016-04-07 | — | — | US | disclosed |
| WO-2014204763-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | ALDH1A1 921/4885CHRNA7 4422/4885PKM 623/4885 |
| US-20160272599-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | ALDH1A1 2044/4885CHRNA7 4694/4885PKM 3994/4885 |
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | ALDH1A1 2044/4885CHRNA7 4694/4885PKM 3994/4885 |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | AHR, MUSK, TYR | ALDH1A1 1806/4885CHRNA7 4381/4885PKM 1767/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | ALDH1A1 299/4885CHRNA7 4393/4885PKM 767/4885 |
| US-20160096802-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | GMPS, GUCY1B2, GUCY1A1 | ALDH1A1 851/4885CHRNA7 3161/4885PKM 332/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | ALDH1A1 2267/4885CHRNA7 3309/4885PKM 1321/4885 |
| US-20170183299-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | GMPS, GUCY1B2, GUCY1A1 | ALDH1A1 851/4885CHRNA7 3161/4885PKM 332/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3208/4885CHRNA7 4866/4885PKM 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.